Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners, and alternate sites of care worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The company offers dental merchandise, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, and PPE products; dental equipment, such as dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair; and branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, and vitamins. It also provides financial services on a nonrecourse basis, education services for practitioners, consulting, and other services; and consumable merchandise under its own brand. In addition, the company manufactures, markets, and sells dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products and other health care-related products and services. Further, it is involved in the development and distribution of practice management software, e-services, and other products to health care providers. The company serves customers in dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics and other alternate care clinics. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Henry Schein Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Henry Schein (HSIC), Insulet (PODD) and Gilead Scien...

Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Insulet (PODD) and Gilead Sciences (GILD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on QuidelOrtho (QDEL), Climb Bio (CLYM) and Henry Sch...

Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Climb Bio (CLYM) and Henry Schein (HSIC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lemaitre Vascular (LMAT), Henry Schein (HSIC) and Exelixis (EXEL)...

Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (LMAT), Henry Schein (HSIC) and Exelixis (EXEL)

Henry Schein (($HSIC)) has held its Q1 earnings call. Read on for the main highlights of the call. Henry Schein’s latest earnings call struck an up...

Henry Schein Earnings Call Highlights Margin Momentum

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Henry Schein (HSIC), Viridian Therapeutics (VRDN) and Q32 Bio (QT...

Market Cap	$8.58B	P/E Ratio	13.92
52W High	$89.29	52W Low	$61.95
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	-25.3%	52W Position	43.7%
Overall Score	49	Value Score	80
Quality Score	39	Technical Score	30

EPS Current Est	$5.31	EPS Next Est	$5.81
EPS Growth Est	+9.4%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HSIC	$73.90	-0.42%	1.23M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HSIC	$73.90	-0.4%	1.23M
3
4
5
6

HSIC

HSIC

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Henry Schein Inc. Data in Excel

Get Henry Schein Inc. Data in Excel